Tiny survey: Your Data has Drugs or Genes?

[Oliver Ruebenacker]

     Hello,

  A tiny survey, please respond quickly:

  - Do you publish data that contains references to
    - drugs?
    - genetic variants?
    - any impact of genetic variants?

  Thanks!

     Take care
     Oliver

--
Head of Systems Biology Task Force at PanGenX (http://www.pangenx.com)
Any sufficiently advanced technology is indistinguishable from magic.

[D'Eustachio, Peter]

yes to all three.
Peter

---

From: biopax-...@googlegroups.com [biopax-...@googlegroups.com] on behalf of Oliver Ruebenacker [cur...@gmail.com]
Sent: Tuesday, May 07, 2013 8:34 AM
To: biopax-...@googlegroups.com
Subject: Tiny survey: Your Data has Drugs or Genes?

--
You received this message because you are subscribed to the Google Groups "BioPAX discussion group" group.
To unsubscribe from this group and stop receiving emails from it, send an email to biopax-discus...@googlegroups.com.
For more options, visit https://groups.google.com/groups/opt_out.
 
 

[Oliver Ruebenacker]

     Hello Peter,

  Thanks for the response. Can you give examples of such data? Perhaps links?

  I'm sure there are also others who have this kind of data. Your contributions will be much appreciated.

     Take care
     Oliver

[D'Eustachio, Peter]

Hello Oliver,

Many of the pathways grouped under “disease” in our event hierarchy involve genetic variants, and in some cases we’ve also annotated reactions of proteins with drugs to modulate the course of a disease. A nice example is signaling by EGFR proteins that have mutated to become constitutively active,  but which as a result now bind to kinase inhibitors that have no affinity for their normal counterparts.

Peter